Search

Your search keyword '"Jordana-Ariza, Núria"' showing total 17 results
Start Over Author "Jordana-Ariza, Núria" Search Limiters Full Text
17 results on '"Jordana-Ariza, Núria"'

3. Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial

Author

Molina-Vila, Miguel-Angel, Stahel, Rolf A., Dafni, Urania, Jordana-Ariza, Núria, Balada-Bel, Ariadna, Garzón-Ibáñez, Mónica, García-Peláez, Beatriz, Mayo-de-las-Casas, Clara, Felip, Enriqueta, Curioni Fontecedro, Alessandra, Gautschi, Oliver, Peters, Solange, Massutí, Bartomeu, Palmero, Ramon, Ponce Aix, Santiago, Carcereny, Enric, Früh, Martin, Pless, Miklos, Popat, Sanjay, Cuffe, Sinead, Bidoli, Paolo, Kammler, Roswitha, Roschitzki-Voser, Heidi, Tsourti, Zoi, Karachaliou, Niki, and Rosell, Rafael

Published
2020
Full Text
View/download PDF

4. Fluorescence In Situ Hybridization (FISH) for the Characterization and Monitoring of Primary Cultures from Human Tumors

Author

Román-Lladó, Ruth, primary, Aguado, Cristina, additional, Jordana-Ariza, Núria, additional, Roca-Arias, Jaume, additional, Rodríguez, Sonia, additional, Aldeguer, Erika, additional, Garzón-Ibañez, Mónica, additional, García-Peláez, Beatriz, additional, Vives-Usano, Marta, additional, Giménez-Capitán, Ana, additional, Aguilar, Andrés, additional, Martinez-Bueno, Alejandro, additional, Cao, María Gonzalez, additional, García-Casabal, Florencia, additional, Viteri, Santiago, additional, Mayo de las Casas, Clara, additional, Rosell, Rafael, additional, and Molina-Vila, Miguel Angel, additional

Published
2023
Full Text
View/download PDF

5. Abstract 1106: Detection of MET alterations at the DNA, RNA and protein levels in NSCLC patients progressing on ALK and ROS1 targeted therapies

Author

Jordana-Ariza, Núria, primary, Reischmann, Nadine, additional, Esparré, Carlos, additional, Román, Ruth, additional, Aguado-Esteban, Cristina, additional, García-Román, Silvia, additional, Stroh, Christopher, additional, Aguilar, Andrés Aguilar, additional, Rosell, Rafael, additional, Karachaliou, Niki, additional, and Molina-Vila, Miguel A., additional

Published
2022
Full Text
View/download PDF

6. Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy

Author

Kallergi, Galatea, primary, Kontopodis, Emmanouil, additional, Ntzifa, Aliki, additional, Jordana-Ariza, Núria, additional, Karachaliou, Niki, additional, Pantazaka, Evangelia, additional, Charalambous, Haris A., additional, Psyrri, Amanda, additional, Tsaroucha, Emily, additional, Boukovinas, Ioannis, additional, Koumarianou, Anna, additional, Hatzidaki, Dora, additional, Lianidou, Evi, additional, Georgoulias, Vassilis, additional, Rosell, Rafael, additional, and Kotsakis, Athanasios, additional

Published
2022
Full Text
View/download PDF

7. Multiplex Detection of Clinically Relevant Mutations in Liquid Biopsies of Cancer Patients Using a Hybridization-Based Platform

Author

Giménez-Capitán, Ana, primary, Bracht, Jillian, additional, García, Juan José, additional, Jordana-Ariza, Núria, additional, García, Beatriz, additional, Garzón, Mónica, additional, Mayo-de-las-Casas, Clara, additional, Viteri-Ramirez, Santiago, additional, Martinez-Bueno, Alejandro, additional, Aguilar, Andrés, additional, Sullivan, Ivana-Gabriela, additional, Johnson, Eric, additional, Huang, Chung-Ying, additional, Gerlach, Jay L, additional, Warren, Sarah, additional, Beechem, Joseph M, additional, Teixidó, Cristina, additional, Rosell, Rafael, additional, Reguart, Noemí, additional, and Molina-Vila, Miguel A, additional

Published
2021
Full Text
View/download PDF

8. RNA-Based Multiplexing Assay for Routine Testing of Fusion and Splicing Variants in Cytological Samples of NSCLC Patients

Author

Aguado, Cristina, primary, Giménez-Capitán, Ana, additional, Román, Ruth, additional, Rodríguez, Sonia, additional, Jordana-Ariza, Núria, additional, Aguilar, Andrés, additional, Cabrera-Gálvez, Carlos, additional, Rivas-Corredor, Carlos, additional, Lianes, Pilar, additional, Viteri, Santiago, additional, Moya, Irene, additional, and Molina-Vila, Miguel A., additional

Published
2020
Full Text
View/download PDF

9. Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions

Author

Villatoro, Sergio, primary, Mayo‐de‐las‐Casas, Clara, additional, Jordana‐Ariza, Núria, additional, Viteri‐Ramírez, Santiago, additional, Garzón‐Ibañez, Mónica, additional, Moya‐Horno, Irene, additional, García‐Peláez, Beatriz, additional, González‐Cao, María, additional, Malapelle, Umberto, additional, Balada‐Bel, Ariadna, additional, Martínez‐Bueno, Alejandro, additional, Campos, Raquel, additional, Reguart, Noemí, additional, Majem, Margarita, additional, Blanco, Remei, additional, Blasco, Ana, additional, Catalán, María J., additional, González, Xavier, additional, Troncone, Giancarlo, additional, Karachaliou, Niki, additional, Rosell, Rafael, additional, and Molina‐Vila, Miguel A., additional

Published
2019
Full Text
View/download PDF

10. Multiplex Detection of Clinically Relevant Mutations in Liquid Biopsies of Cancer Patients Using a Hybridization-Based Platform.

Author

nez-Capitán, Ana Gimé, Bracht, Jillian, García, Juan José, Jordana-Ariza, Núria, García, Beatriz, Garzón, Mónica, Mayo-de-las-Casas, Clara, Viteri-Ramirez, Santiago, Martinez-Bueno, Alejandro, Aguilar, Andrés, Sullivan, Ivana-Gabriela, Johnson, Eric, Chung-Ying Huang, Gerlach, Jay L., Warren, Sarah, Beechem, Joseph M., Teixidó, Cristina, Rosell, Rafael, Reguart, Noemí, and Molina-Vila, Miguel A.

Published
2021
Full Text
View/download PDF

11. Prospective analysis of liquid biopsies of advanced non-small cell lung cancer patients after progression to targeted therapies using GeneReader NGS platform

Author

Mayo de las Casas, Clara, primary, Garzón-Ibañez, Mónica, additional, Jordana-Ariza, Núria, additional, Viteri-Ramírez, Santiago, additional, Moya-Horno, Irene, additional, Karachaliou, Niki, additional, Yeste, Zaira, additional, Campos, Raquel, additional, Villatoro, Sergi, additional, Balada-Bel, Ariadna, additional, García-Peláez, Beatriz, additional, Reguart, Noemí, additional, Teixidó, Cristina, additional, Jantús, Eloisa, additional, Calabuig, Silvia, additional, Aguado, Cristina, additional, Giménez-Capitán, Ana, additional, Román-Lladó, Ruth, additional, Pérez-Rosado, Ana, additional, Catalán, Maria José, additional, Bertrán-Alamillo, Jordi, additional, García-Román, Silvia, additional, Rodriguez, Sonia, additional, Alonso, Lidia, additional, Aldeguer, Erika, additional, Martínez-Bueno, Alejandro, additional, González-Cao, Maria, additional, Aguilar Hernandez, Andrés, additional, Garcia-Mosquera, Juan, additional, de los Llanos Gil, Maria, additional, Fernandez, Manuel, additional, Rosell, Rafael, additional, and Molina-Vila, Miguel Ángel, additional

Published
2018
Full Text
View/download PDF

12. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer

Author

Mayo-de-las-Casas, Clara, primary, Garzón Ibáñez, Mónica, additional, Jordana-Ariza, Núria, additional, García-Peláez, Beatriz, additional, Balada-Bel, Ariadna, additional, Villatoro, Sergio, additional, Malapelle, Umberto, additional, Karachaliou, Niki, additional, Troncone, Giancarlo, additional, Rosell, Rafael, additional, and Molina-Vila, Miguel Angel, additional

Published
2017
Full Text
View/download PDF

13. Evolution and Clinical Impact of EGFRMutations in Circulating Free DNA in the BELIEF Trial

Author

Molina-Vila, Miguel-Angel, Stahel, Rolf A., Dafni, Urania, Jordana-Ariza, Núria, Balada-Bel, Ariadna, Garzón-Ibáñez, Mónica, García-Peláez, Beatriz, Mayo-de-las-Casas, Clara, Felip, Enriqueta, Curioni Fontecedro, Alessandra, Gautschi, Oliver, Peters, Solange, Massutí, Bartomeu, Palmero, Ramon, Ponce Aix, Santiago, Carcereny, Enric, Früh, Martin, Pless, Miklos, Popat, Sanjay, Cuffe, Sinead, Bidoli, Paolo, Kammler, Roswitha, Roschitzki-Voser, Heidi, Tsourti, Zoi, Karachaliou, Niki, and Rosell, Rafael

Abstract

Longitudinal evaluation of mutations in blood samples was a prespecified secondary objective in the BELIEF trial of erlotinib and bevacizumab in advanced EGFR-positive NSCLC. Here, we report the testing results and explore the correlation of EGFRstatus in blood with clinical outcomes.

Published
2020
Full Text
View/download PDF

14. Liquid Biopsy in Non-Small Cell Lung Cancer

Author

Molina-Vila, Miguel A., primary, Mayo-de-las-Casas, Clara, additional, Giménez-Capitán, Ana, additional, Jordana-Ariza, Núria, additional, Garzón, Mónica, additional, Balada, Ariadna, additional, Villatoro, Sergi, additional, Teixidó, Cristina, additional, García-Peláez, Beatriz, additional, Aguado, Cristina, additional, Catalán, María José, additional, Campos, Raquel, additional, Pérez-Rosado, Ana, additional, Bertran-Alamillo, Jordi, additional, Martínez-Bueno, Alejandro, additional, Gil, María-de-los-Llanos, additional, González-Cao, María, additional, González, Xavier, additional, Morales-Espinosa, Daniela, additional, Viteri, Santiago, additional, Karachaliou, Niki, additional, and Rosell, Rafael, additional

Published
2016
Full Text
View/download PDF

15. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.

Author

Mayo-de-las-Casas, Clara, Garzón Ibáñez, Mónica, Jordana-Ariza, Núria, García-Peláez, Beatriz, Balada-Bel, Ariadna, Villatoro, Sergio, Malapelle, Umberto, Karachaliou, Niki, Troncone, Giancarlo, Rosell, Rafael, and Molina-Vila, Miguel Angel

Abstract

Introduction: Collection of tumor samples is not always feasible in non-small cell lung cancer (NSCLC) patients, and circulating free DNA (cfDNA) extracted from blood represents a viable alternative. Different sensitive platforms have been developed for genetic cfDNA testing, some of which are already in clinical use. However, several difficulties remain, particularly the lack of standardization of these methodologies. Areas covered: Here, the authors present a review of the literature to update the applicability of cfDNA for diagnosis and monitoring of NSCLC patients. Expert commentary: Detection of somatic alterations in cfDNA is already in use in clinical practice and provides valuable information for patient management. Monitoring baseline alterations and emergence of resistance mutations is one of the most important clinical applications and can be used to non-invasively track disease evolution. Today, different technologies are available for cfDNA analysis, including whole-genome or exome sequencing and targeted methods that focus on a selection of genes of interest in a specific disease. In the case of Next Generation Sequencing (NGS) approaches, in depth coverage of candidate mutation loci can be achieved by selecting a limited number of targeted genes. [ABSTRACT FROM PUBLISHER]

Published
2018
Full Text
View/download PDF

16. RNA-Based Multiplexing Assay for Routine Testing of Fusion and Splicing Variants in Cytological Samples of NSCLC Patients.

Author

Aguado, Cristina, Giménez-Capitán, Ana, Román, Ruth, Rodríguez, Sonia, Jordana-Ariza, Núria, Aguilar, Andrés, Cabrera-Gálvez, Carlos, Rivas-Corredor, Carlos, Lianes, Pilar, Viteri, Santiago, Moya, Irene, and Molina-Vila, Miguel A.

Subjects
NON-small-cell lung carcinoma, PROTEIN-tyrosine kinases, BIOLOGICAL assay
Abstract

The detection of ALK receptor tyrosine kinase (ALK), ROS proto-oncogen1, receptor tyrosine kinase (ROS1), ret proto-oncogen (RET), and MET proto-oncogen exon 14 skipping (METΔex14) allows for the selection of specific kinase inhibitor treatment in patients with non-small cell lung cancer (NSCLC). Multiplex technologies are recommended in this setting. We used nCounter, a multiplexed technology based on RNA hybridization, to detect ALK, ROS1, RET, and METΔex14 in RNA purified from cytological specimens (n = 16) and biopsies (n = 132). Twelve of the 16 cytological samples (75.0%) were evaluable by nCounter compared to 120 out of 132 (90.9%) biopsies. The geometrical mean (geomean) of the housekeeping genes of the nCounter panel, but not the total amount of RNA purified, was significantly higher in biopsies vs. cytological samples. Among cytological samples, we detected ALK (n = 3), METΔex14 (n = 1) and very high MET expression (n = 1) positive cases. The patient with METΔex14 had a partial response to tepotinib, one of the patients with ALK fusions was treated with crizotinib with a complete response. Cell blocks and cytological extensions can be successfully used for the detection of fusions and splicing variants using RNA-based methods such as nCounter. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

17. Prospective analysis of liquid biopsies of advanced non-small cell lung cancer patients after progression to targeted therapies using GeneReader NGS platform.

Author

Mayo de Las Casas C, Garzón-Ibañez M, Jordana-Ariza N, Viteri-Ramírez S, Moya-Horno I, Karachaliou N, Yeste Z, Campos R, Villatoro S, Balada-Bel A, García-Peláez B, Reguart N, Teixidó C, Jantús E, Calabuig S, Aguado C, Giménez-Capitán A, Román-Lladó R, Pérez-Rosado A, Catalán MJ, Bertrán-Alamillo J, García-Román S, Rodriguez S, Alonso L, Aldeguer E, Martínez-Bueno A, González-Cao M, Aguilar Hernandez A, Garcia-Mosquera J, de Los Llanos Gil M, Fernandez M, Rosell R, and Molina-Vila MÁ

Abstract

Background: In a significant percentage of advanced non-small cell lung cancer (NSCLC) patients, tumor tissue is unavailable or insufficient for genetic analyses at time to progression. We prospectively analyzed the appearance of genetic alterations associated with resistance in liquid biopsies of advanced NSCLC patients progressing to targeted therapies using the NGS platform., Methods: A total of 24 NSCLC patients were included in the study, 22 progressing to tyrosine kinase inhibitors and two to other treatments. Liquid biopsies samples were obtained and analyzed using the GeneRead TM QIAact Lung DNA UMI Panel, designed to enrich specific target regions and containing 550 variant positions in 19 selected genes frequently altered in lung cancer tumors. Previously, a retrospective validation of the panel was performed in clinical samples., Results: Of the 21 patients progressing to tyrosine kinase inhibitors with valid results in liquid biopsy, NGS analysis identified a potential mechanism of resistance in 12 (57%). The most common were acquired mutations in ALK and EGFR , which appeared in 8/21 patients (38%), followed by amplifications in 5/21 patients (24%), and KRAS mutations in one patient (5%). Loss of the p.T790M was also identified in two patients progressing to osimertinib. Three of the 21 (14%) patients presented two or more concomitant alterations associated with resistance. Finally, an EGFR amplification was found in the only patient progressing to immunotherapy included in the study., Conclusions: NGS analysis in liquid biopsies of patients progressing to targeted therapies using the GeneReader platform is feasible and can help the oncologist to make treatment decisions., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2018.10.12). The series “Targeted Therapy and Non-Small Cell Lung Cancer: A New Era?” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare., (2019 Translational Cancer Research. All rights reserved.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results